Liberum Capital Reconfirms a “Buy” Rating on WPP Group PLC (LON:WPP); Roche Holding AG (RHHBY) Had 3 Bullish Analysts

WPP plc (LON:WPP) Logo

WPP Group PLC (LON:WPP) stock had its “Buy” Rating restate by stock analysts at Liberum Capital in an analyst note revealed on Tuesday morning.

Among 5 analysts covering Roche Hldg (OTCMKTS:RHHBY), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Roche Hldg had 9 analyst reports since December 2, 2015 according to SRatingsIntel. The rating was downgraded by Berenberg on Tuesday, October 24 to “Hold”. Cowen & Co maintained the stock with “Buy” rating in Thursday, October 19 report. The stock has “Overweight” rating by Piper Jaffray on Friday, January 22. The firm earned “Buy” rating on Monday, September 18 by Cowen & Co. The firm has “Hold” rating given on Wednesday, October 18 by Citigroup. The rating was maintained by Cowen & Co on Monday, August 14 with “Buy”. The rating was upgraded by Citigroup on Wednesday, December 2 to “Buy”. Cowen & Co maintained the stock with “Buy” rating in Monday, July 10 report. See Roche Holding AG (OTCMKTS:RHHBY) latest ratings:

The stock increased 0.43% or $0.12 during the last trading session, reaching $27.8. About shares traded. Roche Holding AG (OTCMKTS:RHHBY) has 0.00% since May 1, 2017 and is . It has underperformed by 11.55% the S&P500.

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses worldwide. The company has market cap of $190.54 billion. The firm offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, drug metabolism disorder, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, human papillomavirus, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and west nile virus diseases. It has a 21.24 P/E ratio. It also provides diagnostic solutions for blood gas analysis; blood screening; cancer screening; cardiac markers; cardiovascular testing; cholesterol monitoring; coagulation monitoring, routing, and specialty testing; data management; diabetes monitoring and therapy; electrolytes analysis; emergency medicine; hemostasis; heterogeneous immunochemistry; homogenous immune assays; immunology; infectious diseases; intensive care testing; microarray; anti-platelet therapy monitoring; neonatal intensive care; nucleic acid purification; PCR clinical diagnostics and real-time PCR diagnostic systems; pharmacogenomics; physical fitness and platelet function testing; serum work area; urinalysis; and workflow solutions.

Among 25 analysts covering WPP Group PLC (LON:WPP), 14 have Buy rating, 0 Sell and 11 Hold. Therefore 56% are positive. WPP Group PLC has GBX 2250 highest and GBX 1 lowest target. GBX 1597.88’s average target is 28.40% above currents GBX 1244.5 stock price. WPP Group PLC had 331 analyst reports since July 27, 2015 according to SRatingsIntel. JP Morgan maintained WPP plc (LON:WPP) rating on Wednesday, December 9. JP Morgan has “Overweight” rating and GBX 1760 target. The firm has “Hold” rating by Liberum Capital given on Tuesday, December 20. The stock of WPP plc (LON:WPP) earned “Buy” rating by Jefferies on Friday, April 7. The firm has “Market Perform” rating by BMO Capital Markets given on Thursday, August 25. The stock of WPP plc (LON:WPP) earned “Buy” rating by Shore Capital on Monday, October 23. The stock of WPP plc (LON:WPP) has “Buy” rating given on Monday, March 6 by HSBC. The stock of WPP plc (LON:WPP) earned “Buy” rating by Jefferies on Wednesday, November 11. The stock of WPP plc (LON:WPP) earned “Buy” rating by Nomura on Monday, March 7. JP Morgan maintained WPP plc (LON:WPP) on Tuesday, November 10 with “Overweight” rating. The firm has “Buy” rating by UBS given on Monday, February 26.

The stock decreased 0.24% or GBX 3 during the last trading session, reaching GBX 1244.5. About 411,616 shares traded. WPP plc (LON:WPP) has 0.00% since May 1, 2017 and is . It has underperformed by 11.55% the S&P500.

Roche Holding AG (OTCMKTS:RHHBY) Ratings Chart